Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5174 - Micro-RNA profile in advanced metastatic breast cancer as a predictive tool for response to bevacizumab-paclitaxel.


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Translational Research;  Breast Cancer


marta Mendiola


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


M. Mendiola1, V. Heredia-Soto2, J. Herranz3, R. Martín3, P. Zamora Auñón4, B. Castelo4, A. Pinto Marin5, M. Miguel6, R. Crespo7, A. Ramírez de Molina8, D. Hardisson9, E. Espinosa4, A. Redondo10

Author affiliations

  • 1 Molecular Pathology And Therapeutic Target Laboratory, IdIPAZ – Hospital Universitario La Paz, 28046 - Madrid/ES
  • 2 Instituto De Investigación Del Hulp, Idipaz, Hospital Universitario La Paz, HULP, 28046 - Madrid/ES
  • 3 Statistics Unit, IMDEA, Madrid/ES
  • 4 Medical Oncology, Hospital Universitario La Paz, Madrid/ES
  • 5 Medical Oncology, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 6 Molecular Pathology And Therapeutic Targets Laboratory, IdIPAZ – Hospital Universitario La Paz, 28046 - Madrid/ES
  • 7 Translational Oncology Laboratory, IdIPAZ – Hospital Universitario La Paz, Madrid/ES
  • 8 Research Laboratory, IMDEA, Madrid/ES
  • 9 Pathology, Hospital Universitario La Paz, Madrid/ES
  • 10 Medical Oncology Department, Hospital Universitario La Paz, 28046 - Madrid/ES


Abstract 5174


Bevacizumab-containing therapy improves progression-free survival (PFS) in human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (mBC), but its use has been questioned due to the lack of benefit in overall survival (OS). To date, biomarkers to predict its positive effect are not available. Interestingly, miRNAs have emerged as regulators of most processes, forming tight interconnected feedback loops with genes under their regulation. Currently, different analyses, such as microarray, are performed in order to identify miRNA biomarkers, using formalin-fixed and paraffin-embedded (FFPE) tissue samples.


In the present study we recorded clinical data from 57 mBC patients, and selected two (4 + 4) PFS extreme groups for the analysis of the miRnome. Three miRNAs were used for normalization (U6, 191-5p and 103-a-3p). miRNAs for model construction were selected by differential expression between the two groups. Candidates were measured in the remaining 49 cases, and stepwise based Akaike criterion was used for profile generation. Additionally, integrative miRNA and mRNA analyses were done to reveal markers and pathways with potential clinical impact.


We selected two groups of patients with extreme differences on PFS (2.48 ± 1.85 vs 35.43 ±8.03 months) for their miRnome study. The expression profiles of miRNAs in both groups were highly correlated, except for 13 miRNAs where statistical differences arised. These miRNAs were selected as candidates for profile generation on the 49 additional cases, and a combination of five of them (miR-362-3p, miR-150b-5p, miR-671-3p, miR-744-3p and miR-941) was able to accurately discriminate two PFS groups. Additionally, Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses on miRNA possible target genes revealed interesting pathways to explore in these patients, such as cellular adhesion.


By combining experimental approaches and computational biology, we have identified candidate markers of outcome for bevacizumab-containing therapy. The five miRNAs included in the prognostic profile and cellular adhesion related genes should be explored as potential biomarkers.

Clinical trial identification

Legal entity responsible for the study

Fundación para la Investigación del Hospital Universitario La Paz




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.